Employer, Commercial, and Marketplace Plans

The coverage overview explains the two gates every commercial plan applies before any of the criteria below matter.

Employer and commercial plans

This is where coverage varies the most, because most large employers self-fund their plans and set their own rules. Two people with the same insurance card and the same insurer can have completely different coverage.

Sentara Health Plans

Sentara’s criteria (Weight Management Drugs prior authorization form, revised June 11, 2026) are among the more attainable in Virginia:

• BMI of 30 or higher, or BMI of 27 or higher with a qualifying condition
• Participation in a weight-loss treatment plan — nutritional counseling, exercise, or a calorie-restricted diet — within the past six months, continuing during treatment
• Current height, weight, and BMI submitted by your provider
• Not using another GLP-1 concurrently

Initial approval: 7 months. Renewal requires at least 5% weight loss during that period, or maintenance of that loss for subsequent renewals (which run up to 12 months). Authorizations won’t be renewed if BMI falls below 18.5. A formulation catch worth knowing: Sentara’s form specifies Zepbound Pens and states that “Kwikpen/vial formulations are NOT covered.”

UnitedHealthcare

UnitedHealthcare’s commercial criteria (Program 2026 P 1114-21, effective July 1, 2026) apply only if your employer elected weight-loss coverage: BMI of 30 or higher, or 27 or higher with a weight-related condition; used alongside lifestyle modification; age 12 and up for Saxenda, Wegovy injection, and Qsymia, and over 16 for other products.

Initial approval periods differ by drug: Saxenda gets 4 months, Wegovy injection or tablet gets 5 months, Zepbound gets 6 months. Renewal thresholds also differ — 4% weight loss for Saxenda, 5% for Wegovy and Zepbound — and renewals run 12 months. Notably, UnitedHealthcare’s standard commercial criteria do not require step therapy through an older weight-loss drug.

Cigna

Cigna’s coverage policy IP0206, effective June 1, 2026, is titled “Weight Loss – Glucagon-Like Peptide-1 Agonists BMI ≥ 30”:

• Age 18 or older
• At least 3 months of behavioral modification and dietary restriction
• BMI of 30 or higher at baseline, or 27 or higher with a qualifying condition
• Used alongside behavioral modification and a reduced-calorie diet

Initial approval: 8 months for Zepbound and Wegovy; 4 months for Saxenda. Renewal: 1 year, requiring at least 5% weight loss for Zepbound and Wegovy, or at least 4% for Saxenda. Cigna measures against your baseline before any GLP-1, which matters if you’re switching products, and requires documentation for Saxenda specifically — chart notes, lab results, or prescription receipts.

Anthem Blue Cross and Blue Shield

Anthem is Virginia’s largest commercial carrier, and coverage varies widely across its plan types. Anthem requires prior authorization whenever it covers these drugs. Its commercial criteria generally follow the BMI 30, or 27-with-comorbidity standard, with documented lifestyle attempts and a 5% weight-loss requirement for renewal — but many Anthem employer plans exclude weight-loss drugs from the pharmacy benefit entirely. Anthem’s pharmacy benefits are administered by CarelonRx. Because employer groups make the final call, verify your specific plan rather than relying on general Anthem policy.

Aetna

Aetna covers Wegovy and Zepbound for chronic weight management under its clinical policy bulletins, generally at BMI 30 or higher, or 27 or higher with a weight-related condition, plus documented participation in a weight management program. Aetna maintains multiple prior authorization policies that employers can choose between — including a distinct “Weight Loss (BMI 35)” GLP-1 policy with a higher threshold. Aetna also administers the COVA HealthAware plan for Virginia state employees.

CareFirst BlueCross BlueShield and Kaiser Permanente

Both serve Northern Virginia. CareFirst generally covers Wegovy on commercial plans with prior authorization at the BMI 30, or 27-with-comorbidity standard, typically on a higher cost-sharing tier. Kaiser Permanente of the Mid-Atlantic States requires prior authorization and has historically required enrollment in its own clinical pharmacy weight management program as a condition of coverage. Confirm current criteria directly with either plan.

The layer most people don’t know about: your PBM

Your insurer decides your benefits, but a pharmacy benefit manager decides which specific drugs are on the covered list. Three PBMs — CVS Caremark, Express Scripts, and Optum Rx — handle most prescriptions in Virginia, and their decisions can override what you’d expect from your insurer.

The clearest example: CVS Caremark removed Zepbound from its standard commercial formulary in July 2025, pushing patients toward Wegovy. Many people had good results on Zepbound and were forced to switch; a class-action lawsuit followed. This is reversing. Eli Lilly announced on May 28, 2026 that Zepbound returns to CVS Caremark’s formulary by October 1, 2026, with some commercially insured patients paying as little as $25. Express Scripts and Optum Rx already cover Zepbound. The caveat: being on a PBM formulary doesn’t guarantee your plan covers it, because employers still make the final call.

Individual and marketplace plans in Virginia

This means Virginia individual and small-group plans are not required to cover Zepbound, Wegovy, or Saxenda for weight loss, and generally don’t. Two things are worth noting. First, a plan may still cover semaglutide or tirzepatide for a different FDA-approved use — Wegovy for cardiovascular risk reduction, Wegovy for MASH liver disease, or Zepbound for moderate-to-severe obstructive sleep apnea. Second, Virginia’s Bureau of Insurance filed a new benchmark application with CMS in May 2026 for plan year 2028, so this could change.

Notes on each medication

Zepbound (tirzepatide)

Approved for chronic weight management and, separately, for moderate-to-severe obstructive sleep apnea in adults with obesity. Adults 18 and older only. The sleep apnea indication is a meaningful alternative path with its own criteria — generally BMI of 30 or higher plus a documented AHI of 15 or more events per hour.

Watch the device type. Zepbound comes as single-dose vials, the Pen, and the KwikPen, and plans do not treat them interchangeably. Sentara covers the Pens but excludes KwikPen and vial formulations; TRICARE’s form specifies the Pen Injector; the Medicare Bridge covers the KwikPen. If your pharmacy claim rejects, the formulation may be the reason.

Wegovy (semaglutide)

The most broadly covered of the three across Virginia plans, and available as an injection, a tablet, and the higher-dose Wegovy HD. Wegovy carries three separate FDA-approved indications: reducing major cardiovascular events in adults with established cardiovascular disease and obesity or overweight; treating non-cirrhotic MASH with moderate-to-advanced fibrosis; and chronic weight management. The injection can be approved from age 12 in many plans; Wegovy HD and Wegovy tablets are adults only.

Saxenda (liraglutide)

• A generic exists. Generic liraglutide launched in 2025 and is usually the covered option; brand Saxenda has had intermittent supply issues.
• Different renewal math. Most plans require 4% weight loss to continue rather than 5%.
• Shorter initial approvals. Cigna and UnitedHealthcare both approve Saxenda for 4 months initially.
• Daily, not weekly. Wegovy and Zepbound are weekly injections.
• Pediatric use. Approved from age 12 for patients weighing at least 60 kg (about 132 pounds).
• On TRICARE, Saxenda is a non-preferred product.

Frequently asked questions

Other coverage guides